Skip to main content
AI RADARTools
39•11/17/2026, 18:02•2 min read

Isomorphic Labs: Demis Hassabis’s AI drug-discovery startup raises $5B

Executive TL;DR30s read

Isomorphic Labs, Demis Hassabis’s AI drug-discovery startup, has raised $5 billion to scale its IsoDDE platform and move AI-generated drug candidates into later clinical stages.

Isomorphic Labs, the AI drug-discovery startup led by Demis Hassabis, has raised $5 billion in investment.

Formally, it is an Alphabet subsidiary; in practice, it is a DeepMind spin-off guided by Hassabis. Isomorphic Labs’ mission is stated as “Solve All Disease.”

This round included major investors such as Andreessen Horowitz, Greenoaks, and Sequoia Capital, among others. With the $5 billion, Isomorphic Labs plans to scale its proprietary drug-design engine IsoDDE and advance AI-generated drug candidates to the next clinical trial stages and eventually to market.

According to Isomorphic Labs, the goal is to begin a new era of biomedical breakthroughs and give patients next-generation medicines.

Why it matters

Analysis

This is one of the largest funding rounds in AI-driven biomedicine and a signal that AI drug discovery is moving from research pilots to industrial scale. If IsoDDE succeeds, it could accelerate new therapies while intensifying regulatory, ethical and safety scrutiny of AI in medicine.

Discuss in community

Share your questions and insights with developers

Join Telegram
+5 Points
← Back to news feed

Related in Ecosystem

Practical guides, core terminology, and agent skills